- Home
- FE vs BIIB Comparison
FE vs BIIB Comparison
Compare FE & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FE
- BIIB
- Stock Information
- Founded
- FE 1996
- BIIB 1978
- Country
- FE United States
- BIIB United States
- Employees
- FE N/A
- BIIB N/A
- Industry
- FE Electric Utilities: Central
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- FE Utilities
- BIIB Health Care
- Exchange
- FE Nasdaq
- BIIB Nasdaq
- Market Cap
- FE 23.9B
- BIIB 24.2B
- IPO Year
- FE N/A
- BIIB 1991
- Fundamental
- Price
- FE $46.93
- BIIB $175.74
- Analyst Decision
- FE Buy
- BIIB Buy
- Analyst Count
- FE 14
- BIIB 23
- Target Price
- FE $48.67
- BIIB $176.48
- AVG Volume (30 Days)
- FE 4.7M
- BIIB 2.0M
- Earning Date
- FE 10-22-2025
- BIIB 10-30-2025
- Dividend Yield
- FE 3.80%
- BIIB N/A
- EPS Growth
- FE 48.81
- BIIB N/A
- EPS
- FE 2.31
- BIIB 10.97
- Revenue
- FE $14,283,000,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- FE $10.61
- BIIB $2.97
- Revenue Next Year
- FE $3.60
- BIIB N/A
- P/E Ratio
- FE $20.32
- BIIB $15.97
- Revenue Growth
- FE 7.74
- BIIB 4.77
- 52 Week Low
- FE $37.58
- BIIB $110.04
- 52 Week High
- FE $48.20
- BIIB $176.02
- Technical
- Relative Strength Index (RSI)
- FE 59.44
- BIIB 76.31
- Support Level
- FE $45.65
- BIIB $165.75
- Resistance Level
- FE $46.96
- BIIB $170.78
- Average True Range (ATR)
- FE 0.64
- BIIB 5.16
- MACD
- FE 0.04
- BIIB 1.34
- Stochastic Oscillator
- FE 95.30
- BIIB 98.74
About FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with 10 regulated distribution utilities across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).